The DOI matches its Crossref record; the references it cites are not checked yet.
An update of safety of clinically used atypical antipsychotics
Abstract
INTRODUCTION: The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile compared to conventional/'typical' APs. AREAS COVERED: We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND (aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone)). EXPERT OPINION: A critical issue in the treatment with atypical APs is represented by their metabolic side effect profile (e.g. weight gain, lipid and glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis) which may limit their use in particular clinical samples. Electrolyte imbalance, ECG abnormalities and cardiovascular adverse effects may recommend a careful baseline and periodic assessments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent reviews further suggest that asenapine and aripiprazole (longer term use) 809 also may lead to weight gain, but the impact of lurasidone on weight is minimal.810”
In the citing paper
“This is not a concern with all antipsychotics, however; quetiapine, clozapine, and olanzapine will generally have higher rates of sedation compared to ziprasidone, risperidone, and aripiprazole.810”
In the citing paper
“Of the antipsychotics, lurasidone and aripiprazole are considered safe from a cardiac perspective, although aripiprazole may increase the risk for hypotension.810”
In the citing paper
“Among the atypical agents, risperidone, aripiprazole, cariprazine, ziprasidone and lurasidone are more likely to cause EPS, particularly at higher doses.810”
In the citing paper
“Clozapine and olanzapine are associated with the greatest level of risk, followed by quetiapine (particularly in higher doses) and risperidone, with a more minimal impact of aripiprazole, ziprasidone, asenapine, and lurasidone.810”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 167 · Cited by 135
Research works printed but not linked: 22
- Laricchia R, 1956, Encephale, 45, 1197
- WHO, 1992, International monitoring of adverse reactions to drugs: adverse reaction terminology
- Muench J, 2010, American Family Physician, 81, 617
- Bleakley S, 2013, The clozapine handbook
- Prakash C, 1997, Drug Metab Dispos, 25, 206
- Ozdemir V, 2002, Curr Opin Investig Drugs, 3, 113
- Physician Assistants Prescribing R, 2010, JAAPA, 23, 16
- 10.1177/0269881107082944 · DOI · Paper page
- Bishara D, 2009, Neuropsychiatr Dis Treat, 5, 483
- Meltzer HY, 1994, J Clin Psychiatry, 55, 47
- 10.1517/14740338.2015.974549 · DOI · Paper page
- Chandrasekaran PK, 2008, Singapore Med J, 49, 96
- Demler TL, 2011, Innov Clin Neurosci, 8, 35
- Woo YS, 2013, Neuropsychiatr Dis Treat, 9, 1521
- Bymaster FP, 1997, J Clin Psychiatry, 58, 28
- Zhao Z, 2015, Int J Clin Exp Med, 8, 11639
- Gonzalez-Rodriguez A, 2015, Patient Prefer Adherence, 9, 695
- Leysen JE, 1994, J Clin Psychiatry, 55, 12
- Kelly DL, 2001, Psychopharmacol Bull, 35, 66
- Gordon JS, 2012, Cutis, 89, 180
- Li C-H, 2013, Eur Rev Med Pharmacol Sci, 17, 2136
- Campbell N, 2009, Clin Interv Aging, 4, 225
Metadata
- Authors
- Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., Martinotti, G., Mazza, M., Perna, G., Carano, A., De Bartolomeis, A., Di Giannantonio, M., & De Berardis, D.
- Affiliations
- University of Hertfordshire (GB)
- University of Naples Federico II (IT)
- Hermanas Hospitalarias del Sagrado Corazón de Jesús (IT)
- Maastricht University (NL)
- University of Chieti-Pescara (IT)
- Columbia University (US)
- Polyedra Research Group, Teramo, Italy
- University of L'Aquila (IT)
- University of Miami (US)
- NHS, Department of Mental Health ASL Ascoli Piceno, Psychiatric Service of Diagnosis and Treatment, Hospital ‘Maria SS del Soccorso,’ San Benedetto del Tronto, Italy
- Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive and Odontostomatogical Sciences, University of Naples ‘Federico II,’ Napoli, Italy
- New York Psychiatric Institute, Columbia University, New York, NY, USA
- ORCID
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2016-07-04
- Volume
- 15
- Issue
- 10
- Pages
- 1329-1347
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2474134945
- Cited by
- 135
- References
- 167
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 9 · 2023: 11 · 2022: 15 · 2021: 12 · 2020: 16 · 2019: 28 · 2018: 18 · 2017: 10 · 2016: 5
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- atypical antipsychotics, drug safety, tolerability, adverse drug reactions, metabolic side effects, weight gain, diabetes mellitus, diabetic ketoacidosis, electrolyte imbalance, electrocardiographic abnormalities, cardiovascular adverse events, psychosis, aripiprazole, asenapine, quetiapine, olanzapine, risperidone, paliperidone, ziprasidone, lurasidone, clozapine, amisulpride, iloperidone
- MeSH terms
- Cardiovascular Diseases, Electrocardiography, Humans, Metabolic Diseases, Antipsychotic Agents, Water-Electrolyte Balance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An update of safety of clinically used atypical antipsychotics. https://app.cochat.ai/papers/10.1080/14740338.2016.1201475
- The paper
- Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., Martinotti, G., Mazza, M., Perna, G., Carano, A., De Bartolomeis, A., Di Giannantonio, M., & De Berardis, D. (2016). An update of safety of clinically used atypical antipsychotics. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2016.1201475
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.